ArticleBritish journal of pharmacology2002
Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Article in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 111 citations in OpenAlex.
- The effect of intra-articular botulinum toxin A on substance P, prostaglandin EBMC veterinary research · 2017Trial
- Novel Pituitary Actions of TAC4 Gene Products in Teleost.International journal of molecular sciences · 2021Article
- Mast Cell-Specific MRGPRX2: a Key Modulator of Neuro-Immune Interaction in Allergic Diseases.Current allergy and asthma reports · 2021Review
- Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.International journal of molecular sciences · 2020Review
- Efficient synthesis of cyclic amidine-based fluorophoresChemical science · 2020Article
- [Scientific reports · 2019Article
- Substance P modulates bone remodeling properties of murine osteoblasts and osteoclasts.Scientific reports · 2018Article
- Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain.The Journal of biological chemistry · 2014Article
- Hemokinin-1(4-11)-induced analgesia selectively up-regulates δ-opioid receptor expression in mice.PloS one · 2014Article
- Article
- The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.British journal of pharmacology · 2013Article
- The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.TheScientificWorldJournal · 2012Review
- Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.Immunologic research · 2011Article
- Expression and function of human hemokinin-1 in human and guinea pig airways.Respiratory research · 2010Article
- Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist.Nucleic acids research · 2005Article
- Characterization of the endokinins: human tachykinins with cardiovascular activity.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- PepPat, a pattern-based oligopeptide homology search method and the identification of a novel tachykinin-like peptide.Mammalian genome : official journal of the International Mammalian Genome Society · 2003Article
- Mouse Hemokinin-1 Decapeptide Subjected to a Brain-specific Post-translational Modification.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The effects of the novel mammalian tachykinin, hemokinin 1 (HEK-1), have been investigated by radioligand binding and functional in vitro and in vivo experiments. 2. Similar to SP (K(i)=0.13 nM), HEK-1 inhibited in a concentration-dependent manner and with high affinity [(3)H]-substance P (SP) binding to human NK(1) receptor (K(i)=0.175 nM) while its affinity for [(125)I]-neurokinin A (NKA) binding at human NK(2) receptor was markedly lower (K(i)=560 nM). 3. In isolated bioassays HEK-1 was a full agonist at tachykinin NK(1), NK(2) and NK(3) receptors. In the rat urinary bladder (RUB) HEK-1 was about 3 fold less potent than SP. In the rabbit pulmonary artery (RPA) HEK-1 and in the guinea-pig ileum (GPI), HEK-1 was about 500 fold less potent than NKA and NKB, respectively. 4. The responses to HEK-1 were antagonized by GR 82334 in RUB (pK(B)=5.6+/-0.07), by nepadutant in RPA (pK(B)=8.6+/-0.04) and by SR 142801 in GPI (pK(B)=9.0+/-0.2) with apparent affinities comparable to that measured against tachykinin NK(1), NK(2) and NK(3) receptor-selective agonists, respectively. 5. Intravenous HEK-1 produced dose-related decrease of blood pressure in anaesthetized guinea-pigs (ED(50)=0.1 nmol kg(-1)) and salivary secretion in anaesthetized rats (ED(50)=6 nmol kg(-1)) with potencies similar to that of SP. All these effects were blocked by the selective tachykinin NK(1) receptor antagonist, SR 140333. 6. We conclude that HEK-1 is a full agonist at tachykinin NK(1), NK(2) and NK(3) receptors, possesses a remarkable selectivity for NK(1) as compared to NK(2) or NK(3) receptors and acts in vivo experiments with potency similar to that of SP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.